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Efﬁcacy of transdermal 4% lidocaine patches for postoperative pain
management after arthroscopic rotator cuff repair: a prospective trial
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Background: Postoperative pain management continues to be a challenging aspect of patient care.
Lidocaine patches have shown efﬁcacy in reducing pain in other surgical specialties and mixed results in
orthopedic trials. We sought to determine the effectiveness of nonprescription lidocaine patches in
reducing postoperative pain after arthroscopic rotator cuff repair
Methods: Patients undergoing primary arthroscopic rotator cuff repair were recruited from 3 surgeons
at a single institution. All patients of each surgeon were randomized to a lidocaine patch or control
group, with crossover occurring at the midpoint. Experimental group patients received 26 4% lidocaine
gel-patches. They were provided written and visual instructions to begin wearing the lidocaine patches
during daytime on postoperative day (POD) 2. They were to be switched every 8 hours and removed
overnight. Control group patients received normal standard of care but did not receive a placebo control.
Exclusion criteria included workmen’s compensation claims, age <18 years, history of myocardial
infarction, and history of lidocaine or adhesive allergies. The American Shoulder and Elbow Surgeons
shoulder survey was completed preoperatively and 2-, 6-weeks, 3-, 4.5-, and 6-months postoperatively.
A 14-day visual analog scale pain and medication log was completed three times daily following repair.
All patients received interscalene nerve block with bupivacaine and general anesthesia.
Results: 80 (40 control, 40 lidocaine) patients were enrolled, with 53 completing follow-up. Groups
were demographically similar in age (P ¼ .22), gender (P ¼ .20), and body mass index (P ¼ .77). They were
similar in tear pattern (P ¼ .95), concomitant acromioplasty (P ¼ .44), concomitant biceps tenodesis
(P ¼ .07), and number of anchors used (P ¼ .25). There was no difference in American Shoulder and Elbow
Surgeons scores at any time points (range P ¼ .28-P ¼ .97). Reported 14-day pain logs were not different
between study groups at any time points (range P ¼ .07-P ¼ .99). There was no difference in opioid
consumption in the ﬁrst 14 days after surgery (P ¼ .38). The lidocaine group reported less satisfaction
with their pain management beginning in the evening of POD 2 (P ¼ .05). This continued until the afternoon of POD 8 (P ¼ .03).
Conclusion: Transdermal 4% lidocaine patches are not effective in reducing pain or opioid consumption
after arthroscopic rotator cuff repair and were associated with reduced patient satisfaction.
© 2021 The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

Although orthopedic surgeons continue to improve functional
outcomes and surgical technique in rotator cuff repair, postoperative pain management continues to be a challenging aspect of
patient care. Opioid medications are often the ﬁrst-line treatment
for postoperative pain; however, they are associated with deleterious effects such as constipation, respiratory depression, and
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dependence. Multiple strategies have been investigated to decrease
the need for narcotic use after surgery. One strategy that warrants
investigation is the use of transdermal lidocaine patches.
Lidocaine patches allow for the local absorption of lidocaine into
a speciﬁc area. The lidocaine inhibits neuron activity, temporarily
relieving pain. Five-percent prescription lidocaine patches have
received Food and Drug Administration approval for post-herpetic
neuralgia; however, both prescription and nonprescription patches
have been used off-label for relief of pain secondary to other conditions. Although it is commonly thought that only superﬁcial pain
can be mediated by patches, there is evidence that ‘deeper’ nerve
pain may be alleviated by 5% transdermal lidocaine (T5L) patches as

https://doi.org/10.1016/j.jseint.2021.09.006
2666-6383/© 2021 The Authors. Published by Elsevier Inc. on behalf of American Shoulder and Elbow Surgeons. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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well.6 This has spurred interest in the use of T5L to alleviate pain
secondary to trauma and surgery, across multiple disciplines.3,8,1113,15
In orthopedics, clinical trials evaluating the use of T5L after
total knee arthroplasty have shown mixed results. A randomized
trial evaluating the use of T5L after arthroplasty found decreased
pain at 1 day, 2 days, 3 days, and 2 weeks postop, as well as
decreasing opioid medication consumption.14 In contrast, another
study investigating the use of T5L during inpatient rehabilitation
after total knee arthroplasty (TKA) found that there was actually an
increase in pain associated with T5L patch use.10
Pain management after arthroscopic rotator cuff repair is largely
dependent on opioid medication use and a nerve blockade in the
immediate postoperative period. Identiﬁcation of effective nonopioid pain management modalities, such as lidocaine patches, is
essential for the improvement of postoperative pain management.
There is some evidence that over-the-counter lidocaine patches
may be equal in efﬁcacy to T5L.2 If nonprescription lidocaine
patches can decrease postoperative pain, they would serve as an
easily accessible and inexpensive option. The aim of this study was
to evaluate the effectiveness of nonprescription lidocaine patches
in reducing postoperative pain after arthroscopic rotator cuff repair.
A secondary aim was to evaluate the effectiveness of lidocaine
patch therapy in reducing opioid consumption. We hypothesized
that the use of lidocaine patches would decrease postoperative pain
and opioid consumption after arthroscopic rotator cuff repair.

arthroscopic portal sites. Beginning on postoperative day (POD) 2,
experimental group patients were instructed to wear the lidocaine
patches during daytime through POD 14. They were to be switched
every 8 hours and removed overnight. Control group patients
received normal standard of care; they did not receive placebo
patches.
Patient recruitment and group assignment
Patient eligibility screening was performed by research staff
who played no role in clinical care. Eligible patients were interviewed by the same research staff to verify eligibility in private,
clinical examination rooms. Patients were assigned to treatment
groups based on their surgeon. Individual surgeons were randomly
assigned to one of two treatment arms at the onset of the study and
blinded to assignment. If a surgeon was assigned to the experimental group, all enrolled patients of that surgeon received lidocaine patches. At the midpoint of enrollment, surgeons switched
treatment arms. If a surgeon’s patients were formerly receiving
lidocaine patches, for the remainder of the study, the enrolled patients for that surgeon were in the control group. Patients were
blinded to the other arm of the study. Informed consent was obtained in accordance with institutional review boardeapproved
consent forms. Patients were debriefed about the intent of the
study and group assignment at their 6-week follow-up visit with a
preapproved debrieﬁng script.

Methods
Outcome measures
Study protocol was approved by our institutional review board
before voluntary patient enrollment. This was a prospective, provider cross-over design trial performed at a single institution to
determine the efﬁcacy of transdermal lidocaine patches in controlling postoperative pain. Eighty patients undergoing primary
arthroscopic rotator cuff repair with one of three board-certiﬁed,
fellowship-trained, sports medicine orthopedic surgeons were
recruited. Exclusion criteria included the following: (1) age under
18 years old, (2) pregnancy, (3) patients with known lidocaine or
adhesive allergies, (4) patients with history of cardiac arrhythmias
or myocardial infarction, (5) irreparable tears, and (6) patients with
workmen’s compensation claim or pending litigation.

Patients in both groups were asked to complete the American
Shoulder and Elbow Surgeons (ASES) Standardized Shoulder
Assessment Form preoperatively and at 2 weeks, 6 weeks, 3
months, 4.5 months, and 6 months postoperatively. They were also
asked to complete a custom 5-question visual analog scale pain and
opioid medication log 3 times daily (morning, afternoon, and
evening), POD 0-POD 14. Average pain, pain at rest, pain with activity, and satisfaction with pain management were assessed.
Opioid medication usage and dosing were also to be logged. Preoperative and long-term usage of analgesics was compared using
ASES questionnaire item 4: “Do you take pain killers such as
paracetamol (acetaminophen), diclofenac, or ibuprofen?” and item
5: “Do you take strong pain killers such as codeine, tramadol, or
morphine?”. Patient demographics of age, gender, and body mass
index (BMI) were collected as well. A minimal clinically important
difference (MCID) of 1.5 was used to compare pain scores.4 An MCID
of 26.9 was used to compare ASES scores.5

Treatment
There were two arms to this study, experimental and control. All
patients received general anesthesia and a liposomal bupivacaine
interscalene nerve block, performed by a board-certiﬁed anesthesiologist. The postoperative medication regimen consisted of 30
oxycodone 10-mg tablets and Zofran 4-mg tablets. Cryo cuff and
nonsteroidal anti-inﬂammatory drug usage was allowed. All patients were treated with a uniformly homogenous therapy program. Sling immobilization was carried out for 4 weeks after
surgery, with passive range of motion allowed out of the sling
during this initial phase. After 4 weeks, the sling was discontinued,
and active assisted range of motion was allowed with progression
to active range of motion by 8 weeks. At 10 weeks after surgery,
patients were begun on a progressive strengthening program
which was continued until 16 weeks after surgery, at which time
patients were transitioned to a home exercise program. Release to
full activity was permitted at 6 months after surgery.
The experimental group received 26 Salonpas (Hisamitsu Co.,
Tosu, Japan) 4% lidocaine gel patches. They were provided with a
printed page of instructions on how and when to apply patches
(Supplementary Appendix S1), in addition to a verbal explanation
at the time of enrollment. Instructions described cutting the patch
in half and applying them superiorly and inferiorly to the

Power statistical analysis
Sample size was determined using the MCID for visual analog
scale postoperative pain scores, 80% power, and prior clinical data. A
total of 29 patients in each group were needed to achieve 80% power.
This was increased to 40 in each group to account for attrition. Statistical analysis was performed by a statistician who is independent
of the research team. Categorical data were analyzed with chisquared tests, and continuous data were analyzed with t-tests or
Mann-Whitney tests. A P value of <.05 was considered signiﬁcant.
Results
Study population
Eighty patients were enrolled in this study. Twenty-seven (34%)
of the study population were excluded from ﬁnal analysis. One
patient had an allergic reaction from hives and discontinued study
105
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Figure 1 CONSORT diagram.

participation. One patient had postoperative atrial ﬁbrillation and
was asked not to start lidocaine patch usage. One patient canceled
surgery after enrollment. One patient asked to withdraw from the
study after enrollment. Twenty-three patients were lost to followup or had incomplete recording of data (Fig. 1).
The 53 patients included for ﬁnal analysis consisted of 28 male
and 25 female patients with a mean age of 61.5 ± 9.5 and a mean
BMI of 30.2 ± 5.9. The 27 patients excluded from analysis consisted
of 12 male and 15 female patients with a mean age of 61.3 ± 8.9 and
a mean BMI of 27.6 ± 4.7. There was no difference in demographics
between patients who completed follow-up and those who did not.
The experimental group had 17 male and 11 female patients with a
mean age of 59.9 ± 11.3 and a mean BMI of 30.5 ± 6.7. The control
group had 11 male and 14 female patients with a mean age of
63.3 ± 6.9 and a mean BMI of 30.0 ± 5.0. Demographics were similar
between the treatment and control groups (Table I).
There were no statistical differences between the treatment and
control groups with regard to arthroscopically conﬁrmed rotator
cuff tear pattern, concomitant procedures (acromioplasty, biceps
tenodesis), or number of suture anchors used (Supplementary
Appendix S3). There were three partial thickness supraspinatus
tears, thirteen full thickness supraspinatus tears, six full thickness
supraspinatus tear þ partial thickness tears of an additional tendon,
and six full thickness of two or more tendons in the treatment
group. There were two partial thickness supraspinatus tears, eleven
full thickness supraspinatus tears, seven full thickness supraspinatus tear þ partial thickness tears of an additional tendon, and
ﬁve full thickness of two or more tendons in the control group.
Concomitant acromioplasty was performed in 13 of treatment

group patients vs. 9 of the control. Biceps tenodesis was performed
in 10 of the treatment group vs. 15 of the control. In the treatment
group, there were 2 zero-anchor (collagen patch), 5 two-anchor, 11
three-anchor, 4 four-anchor, 2 ﬁve-anchor, 1 six-anchor, and 3
seven-anchor repairs performed. In the control group there were
0 zero-anchor (collagen patch), 8 two-anchor, 8 three-anchor, 7
four-anchor, 2 ﬁve-anchor, 0 six-anchor, and 0 seven-anchor repairs performed.
Functional outcomes
Preoperatively, the mean experimental group ASES score was
not different from the control group (50.7 ± 26.1 vs. 43.2 ± 13.8;
P ¼ .31). There was also no difference between groups at the 2week, 6-week, 3-month, 4.5-month, and 6-month follow-up surveys (Table II). At 6 months postoperatively, the mean ASES score
for the experimental group and control group was 88.1 ± 11.7 and
89.6 ± 8.9 (P ¼ .68), respectively. Both groups demonstrated
improvement in ASES scores at 6 months postoperatively,
compared with preoperative scores (P < .01 for both). ASES
improvement for both groups exceeded the MCID of 26.9 (Table II).
Pain management
Preoperatively, there was no difference in reported “pain
medication” use such as paracetamol (acetaminophen), diclofenac,
or ibuprofen (P > .99). There was also no difference in reported
“strong pain killer” usage such as codeine, tramadol, or morphine
(P > .99). At 2 weeks, the experimental group reported taking more

Table I
Patient demographics.
Demographics

Lidocaine (n ¼ 28)

Control (n ¼ 25)

P values

Excluded (n ¼ 27)

Gender (M/F)
Age (y)
BMI (kg/m)

17/11
59.89 (±59.89)
30.46 (±6.68)

11/14
63.32 (±6.91)
29.99 (±5.04)

.20
.22
.77

12/15
61.33 (±8.89)
27.61 (±4.65)

BMI, body mass index.
Data presented as mean ± standard deviation.
P values represent comparisons between the lidocaine and control groups.
106

D. Lee, R.E. Campbell, M.L. Leider et al.

JSES International 6 (2022) 104e110

Table II
ASES score.
Time point

Lidocaine

Control

P values

Preoperative
2 weeks
6 weeks
3 months
4.5 months
6 months

50.68
47.09
57.86
75.95
80.68
88.12

43.22
45.10
57.64
73.94
85.88
89.55

.31
.69
.97
.75
.28
.68

(±26.14)
(±19.81)
(±17.32)
(±19.27)
(±16.10)
(±11.71)

(±13.75)
(±11.91)
(±16.38)
(±17.40)
(±12.59)
(±8.87)

ASES, American Shoulder and Elbow Surgeons.
Data presented as mean ± standard deviation.

Table III
Opioid usage.
Usage duration

Lidocaine (n ¼ 28)

Control (n ¼ 25)

P value

Day 0 þ 1
Day 2-14
Total cumulative

12.46 (±13.70)
68.57 (±94.62)
81.03 (±95.11)

9.3 (±14.89)
49.35 (±79.43)
58.65 (±87.50)

.43
.43
.38

Data in morphine milligram equivalents.

Figure 2 Reported pain levels at rest. M, morning; A, afternoon; E, evening.

“pain medications” overall (P ¼ .04), but not “strong pain killers”
(P ¼ .08). This difference resolved by 6 weeks (P ¼ .17) and remained
nondifferent up to 6 months postoperatively.
Reported opioid medications were converted into morphine
milligram equivalents (MMEs). Cumulative MME consumption
from POD 0 and POD 1, before the experimental group initiating
lidocaine patch therapy, was not different between groups (P ¼ .43).
Day 2-14, after lidocaine patch therapy, demonstrated no difference
between groups for cumulative MME consumed (P ¼ .43). Total
cumulative MME consumption was not different between groups
(P ¼ .38) (Table III).

Reported pain levels and satisfaction were compared for each
distinct asked question (pain at rest, pain with activity, average
pain, satisfaction with pain management) at each time point
(Supplementary Appendix S2). There were no differences between
groups for pain at rest, pain with activity, and average pain for any
time point from POD 0 to POD 14 (Figs. 2-4). The experimental
group reported less satisfaction with their pain management,
beginning in the evening of POD 2 (83.0 ± 24.8 vs. 64.4 ± 34.2;
P ¼ .05). This continued until the afternoon of POD 8 (84.0 ± 26.2 vs.
62.1 ± 35.2; P ¼ .03) and recurred one more time in the evening of
POD 9 (85.4 ± 24.1 vs. 66.8 ± 33.8; P ¼ .04) (Fig. 5).
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Figure 3 Reported pain levels with activity. M, morning; A, afternoon; E, evening.

Figure 4 Reported average pain level. M, morning; A, afternoon; E, evening.

cuff repair, as no differences in pain levels or opioid consumption
were found between the treatment and control groups. In fact,
patients reported lower satisfaction with their pain control when
given lidocaine patches.
Many of the studies reporting on the analgesic effects of lidocaine patches examine nonorthopedic procedures, and thus, results

Discussion
There is evidence in the literature supporting the idea that
lidocaine patches are effective in reducing postoperative pain and
even reducing opioid consumption after surgery.8,11,12 Our ﬁndings
do not support a similar conclusion for patients undergoing rotator
108
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Figure 5 Satisfaction with pain management. M, morning; A, afternoon; E, evening. *Statistically signiﬁcant at P ¼ .05.

may not be transferrable to orthopedic surgery.8,11,12 Kwon et al
reported results on patients undergoing laparoscopic gynecologic
surgery,11 Habib et al on radical retropubic prostatectomy,8 and Lee
et al on laparoscopic appendectomy12; all three studies found improvements in reported pain levels with transdermal lidocaine
patch use. Pathologies of the appendix, prostate, and gynecologic
structures have referred pain due to inﬂammation or pressure due
to growths. Thus, pain after these procedures was most likely due
to superﬁcial incisional pain, rather than at the surgical site. The
pain of rotator cuff pathology is complex and multifactorial.1 Incisional pain from portal sites is not likely the predominant source of
pain after rotator cuff repair, which likely accounts for the lack of
efﬁcacy in this trial.
In the orthopedic literature, T5L patches have been investigated
in rib fractures and arthroplasty. Prior studies have demonstrated
the efﬁcacy of lidocaine patches in the treatment of traumatic rib
fractures, with Zink et al and Cheng et al reporting signiﬁcant reductions in pain for rib fractures in trauma patients.3,15 Sadigursky
et al, who performed a trial evaluating the use of T5L patches after
TKA, found that the T5L patches decreased narcotic consumption
and postoperative pain.14 Conversely, Khanna et al evaluated 53
patients after TKA and discovered that there was an increase in pain
associated with T5L patch use.10 The mechanism by which lidocaine
patches alleviate pain in some musculoskeletal injuries, and not
others, is likely secondary to the depth of the injured tissues and
the ability of transdermal application to penetrate the soft tissues
surrounding traumatized tissue. Ribs are relatively superﬁcial
structures with a thin layer of overlying skin and soft tissue, and in
addition, some knee replacement discomfort may be associated
with a signiﬁcant amount of incisional pain. Arthroscopic rotator
cuff repair has very little incisional pain secondary to the relatively
small portal sites, and the structures repaired are deep to both skin
and muscle, making penetration by a transdermal patch less likely.
Although pain due to superﬁcial vs. deep structures is a possible
reason for the lack of reported pain differences in our patient cohorts, it does not explain dissatisfaction with pain management.

This may be explained by the noneplacebo-controlled nature of our
study. The perception of pain is complex and involves psychosocial
components.9 Our control group was blind to the existence of an
experimental cohort. Thus, they had no placebo or any expectations
for increased pain relief. Our experimental group may have had the
expectation of better pain control with lidocaine patches. Meeting
patient expectations for pain management is an important aspect
of achieving patient satisfaction.7 If the patches did not provide
adequate pain control on par with patient expectations, that could
have resulted in dissatisfaction with the care provided.
Finally, our ﬁndings may be due to the use of 4% over-thecounter transdermal lidocaine patches rather than 5% prescription patches. Although there are studies showing that these may be
noninferior,2 to our knowledge, this is the ﬁrst investigation of 4%
lidocaine patches in postoperative patients. This is a 20% reduction
in dose, which may be more pronounced in studies of nonsuperﬁcial sources of pain. We chose 4% because of its ease of
application, over-the-counter availability, and generalizability of
our ﬁndings because of these attributes.
A limitation of this study is the high attrition rate in this study.
Only 66% (53) of enrolled patients were available for analysis. If
attrition disproportionately accounted for patients who experienced low or high levels of pain, or had disproportionate levels of
satisfaction, this may impact the ﬁnal results. Such a signiﬁcant
dropout can lead to underpowered ﬁndings: our results showing
transdermal lidocaine patches are ineffective in controlling postoperative pain may be incorrect. Another limitation is the experimental design. A provider treatment cross-over design was used
rather than a completely randomized trial. This may lead to subtle
differences in experimental vs. control groups that may not be
detected by basic demographic characteristics. There was also lack
of a placebo control in this study. Chronic pain patients were not
explicitly excluded from the trial. We did not control for preoperative tear pattern. Although there was no statistical difference in
tear pattern between groups, there was a wide range from partial
thickness supraspinatus tears to massive rotator cuff tears with
109
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Conclusion
Four-percent transdermal lidocaine patches are not effective in
reducing postoperative pain or opioid consumption after arthroscopic rotator cuff repair. In addition, patients using the lidocaine
patch experience less satisfaction with their pain management after rotator cuff surgery.
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